Lindbrook Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Lindbrook Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,000	Closed	-$68K	–	2093
2021 Q3	$68K	Buy	+14,000	New	+$41.4K	0.02%	356

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Lindbrook Capital's CRVS Position: Q4 2021 in Review

Lindbrook Capital sold out of Corvus Pharmaceuticals (CRVS) in Q4 2021, closing a stake of 14,000 shares — an estimated $68K sold.

Lindbrook Capital first reported a position in CRVS in Q3 2021 and held it in 1 quarter. The position peaked at $68K in Q3 2021. 62 funds tracked by Wall St. Rank hold CRVS as of Q4 2021.

Lindbrook Capital reported no remaining Corvus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Lindbrook Capital sold 14,000 Corvus Pharmaceuticals shares in Q4 2021, an estimated $68K.
Lindbrook Capital first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Lindbrook Capital's Corvus Pharmaceuticals position peaked at $68K in Q3 2021.
62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2021.

Based on Lindbrook Capital's 13F filing for Q4 2021, filed 18 Jan 2022.